Multicenter assessment of transdermal therapy in overactive bladder with oxybutynin TDS (MATRIX).

Trial Profile

Multicenter assessment of transdermal therapy in overactive bladder with oxybutynin TDS (MATRIX).

Completed
Phase of Trial: Phase IV

Latest Information Update: 17 Jan 2013

At a glance

  • Drugs Oxybutynin (Primary)
  • Indications Overactive bladder
  • Focus Therapeutic Use
  • Acronyms MATRIX
  • Most Recent Events

    • 22 Sep 2011 Actual end date (May 2005) added as reported by ClinicalTrials.gov.
    • 10 Apr 2007 Status change
    • 10 Apr 2007 Status changed from in progress
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top